The third edition of this global standard guide for validated pharmaceutical analysis now incorporates the 2023 ICH guidelines Q2 and Q14, and new sections on data integrity and continuous monitoring.
The third edition of this global standard guide for validated pharmaceutical analysis now incorporates the 2023 ICH guidelines Q2 and Q14, and new sections on data integrity and continuous monitoring.
Joachim Ermer worked for 30 years in the pharmaceutical industry, including analytical development, global responsibilities, Head of Quality Control, and head of QC Lifecycle Management, before he started in December 2020 his consultancy business. Phil W. Nethercote was the analytical leader for the Global Manufacturing and Supply Division of GSK until he retired in 2016. He has over 30 years of experience in the pharmaceutical industry, the majority of which has been with Glaxo, Glaxo Wellcome and GSK.
Inhaltsangabe
1. Analytical Validation within the Pharmaceutical Lifecycle 2. Data Governance, Data Integrity and Data Quality 3. Analytical Instrument Qualification & System Validation Lifecycle 4. Continued HPLC performance qualification 5. Analytical Target Profile 6. Decision Rules and Fitness for Intended Use 7. Performance Characteristics of Analytical Procedures 8. ICHQ14 Analytical Procedure Development 9. Method Selection, Development, and Optimization 10. Multivariate Analytical Procedures 11. Case Study: Robustness Investigations 12. Risk Assessment and Analytical Control Strategy 13. ICH Q2(Revision 2): Validation of Analytical Procedures 14. Case Study: Validation of an HPLC Method for Identity, Assay, and Degradation Products 15. Case Study: Design and Qualification of a Delivered Dose Uniformity Procedure for a Pressurised Metered Dose Inhaler with a Focus on Sample Preparation. 16. Case Study: Validation of a Bioassay Method 17. Implementation of Compendial/Pharmacopeia Test Procedures 18. Transfer of Analytical Procedures 19. Lifecycle Approach to Transfer of Analytical Procedures 20. Continuous Improvements, Adjustments and Changes 21. Monitoring of Analytical Performance
1. Analytical Validation within the Pharmaceutical Lifecycle 2. Data Governance, Data Integrity and Data Quality 3. Analytical Instrument Qualification & System Validation Lifecycle 4. Continued HPLC performance qualification 5. Analytical Target Profile 6. Decision Rules and Fitness for Intended Use 7. Performance Characteristics of Analytical Procedures 8. ICHQ14 Analytical Procedure Development 9. Method Selection, Development, and Optimization 10. Multivariate Analytical Procedures 11. Case Study: Robustness Investigations 12. Risk Assessment and Analytical Control Strategy 13. ICH Q2(Revision 2): Validation of Analytical Procedures 14. Case Study: Validation of an HPLC Method for Identity, Assay, and Degradation Products 15. Case Study: Design and Qualification of a Delivered Dose Uniformity Procedure for a Pressurised Metered Dose Inhaler with a Focus on Sample Preparation. 16. Case Study: Validation of a Bioassay Method 17. Implementation of Compendial/Pharmacopeia Test Procedures 18. Transfer of Analytical Procedures 19. Lifecycle Approach to Transfer of Analytical Procedures 20. Continuous Improvements, Adjustments and Changes 21. Monitoring of Analytical Performance
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
